308nm UVB Phototherapy Lamp for Vitiligo, Psoriasis & Eczema

308nm UVB Phototherapy Lamp for Vitiligo, Psoriasis & Eczema

Sale price  €195,19 Regular price €286,00
Skip to product information
308nm UVB Phototherapy Lamp for Vitiligo, Psoriasis & Eczema

308nm UVB Phototherapy Lamp for Vitiligo, Psoriasis & Eczema

Sale price  €195,19 Regular price €286,00
Details

This portable 308nm UVB lamp provides a non-invasive, drug-free light therapy option for home treatment of vitiligo, psoriasis, and eczema. Its rechargeable design, adjustable dosage, and straightforward controls make it suitable for incorporating targeted phototherapy into a daily routine.

How 308nm UVB Phototherapy Works

The device directs 308nm UVB light toward the treatment area. This wavelength is intended to target T cells that can harm melanocytes and induce apoptosis in specific T cells, supporting the skin’s healing process.

  • Supports melanin production: Stimulates melanocytes to produce melanin and encourage skin pigmentation.
  • Promotes UVB energy absorption: Melanocytes absorb the energy, which may enhance blood circulation and support epidermal cell recovery.

Product Features

  • Rechargeable operation: Use the lamp without a constant wired connection, with long-lasting rechargeable performance.
  • Consistent output: Designed to provide accurate and reliable treatment delivery.
  • Simple controls: User-friendly operation helps integrate sessions into your regular routine.
  • Safety-focused design: Built to support a secure treatment experience when used as directed.

How To Use

  1. Clean the target area: Wash and prepare the skin before treatment.
  2. Apply the recommended ointment or photosensitive substance: Use the suggested product to support treatment effectiveness.
  3. Wear protective glasses: Protect your eyes during each therapy session.
  4. Set the dosage and begin irradiation: Adjust the dosage to personalise the session, then start the lamp.
  5. Use once daily: Follow a daily routine, with visible improvements reported as early as four weeks.

You might also like...